Aripiprazole as second-line pharmacotherapy for a heterogeneous cohort of refractory functional dizziness disorders: a pilot preliminary retrospective study - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating Aripiprazole as a Secondary Treatment Option for Diverse Cases of Persistent Functional Dizziness: A Preliminary Retrospective Analysis

  • By

  • Fumiyuki Goto

  • Koichiro Wasano

  • June 3, 2026

Share

Original Source(s)

Aripiprazole as second-line pharmacotherapy for a heterogeneous cohort of refractory functional dizziness disorders: a pilot preliminary retrospective study

  • by Fumiyuki Goto, Koichiro Wasano

  • June 3, 2026

Related Content

Recent progress in postoperative nausea and vomiting after thyroidectomy

Hand-side matching in TOETVA: assessing feasibility and surgical outcomes through learning curve and propensity score-matched cohorts

Photo-based deep learning for detection of pediatric adenoid hypertrophy